Trending...
- Double the Terror: NYC Halloween Film Festival Returns With Two Nights of Frights
- Max Tucci launches The Osborn Fall WellSpring Series, October 10th, 2024 Rye, New York
- Two Nights of Frights: NYC Halloween Film Festival Returns with a Vengeance
MANHATTAN, N.Y. - Nyenta -- DKBmed LLC is developing an interactive, case-based, two-part educational program to address the emerging knowledge gaps faced by clinicians who treat patients with lung cancer. Entitled Oncology Innovations: The Role of Liquid Biopsy in Lung Cancer Management, this initiative will examine the role of liquid biopsies on treatment selection and illustrate how to optimize patient care through the "Do It Better" learning format. Additionally, a "virtual concierge" will locate a nearby lab to perform the tests, put clinicians in contact with these labs and assist with payer challenges (US only). This program is a further expansion of DKBmed's Oncology Innovations brand that's focused on providing vital education for oncologists and other providers who treat patients with cancer.
With approximately 236,000 new cases diagnosed alone in the United States in 2021, lung cancer is the second most diagnosed cancer globally after breast cancer. Although 5-year survival rates exceed 60% for patient subsets whose cancers were diagnosed in earlier stages, a majority of lung cancer cases are diagnosed in advanced stages. In this setting, where the cancer has metastasized to the brain and bones, between 3% and 9% of patients live past 5 years. To achieve optimal outcomes, the National Comprehensive Cancer Network stresses the importance of molecular profiling of the tumor using biomarkers detected with biopsies. Among the most exciting advances in the management of advanced lung cancer is the liquid biopsy, which detects circulating tumor DNA and other biomarkers shaded in the bloodstream. Liquid biopsy is a versatile tool that enables clinicians to noninvasively identify the most suitable therapy for each individual patient and monitor the response to treatments.
More on Nyenta.com
"Traditional biopsies can be costly, invasive, and ultimately infeasible for many patients with advanced, metastatic lung cancer who have poor performance status. As more targeted treatments gain approval and complicate clinical decision-making, oncology care providers will need greater familiarity with next-generation tools that allow us to realize the fullest potential of precision oncology. A wider adoption of liquid biopsy, namely cell-free DNA analysis, is eagerly awaited," notes Christian Rolfo, MD, PhD, president of the International Society of Liquid Biopsy and deputy chair of the Educational Committee at the International Association for the Study of Lung Cancer.
In Oncology Innovations: The Role of Liquid Biopsy in Lung Cancer Management, participants will:
More on Nyenta.com
With approximately 236,000 new cases diagnosed alone in the United States in 2021, lung cancer is the second most diagnosed cancer globally after breast cancer. Although 5-year survival rates exceed 60% for patient subsets whose cancers were diagnosed in earlier stages, a majority of lung cancer cases are diagnosed in advanced stages. In this setting, where the cancer has metastasized to the brain and bones, between 3% and 9% of patients live past 5 years. To achieve optimal outcomes, the National Comprehensive Cancer Network stresses the importance of molecular profiling of the tumor using biomarkers detected with biopsies. Among the most exciting advances in the management of advanced lung cancer is the liquid biopsy, which detects circulating tumor DNA and other biomarkers shaded in the bloodstream. Liquid biopsy is a versatile tool that enables clinicians to noninvasively identify the most suitable therapy for each individual patient and monitor the response to treatments.
More on Nyenta.com
- New Rochelle: Main Street Overnight Paving Begins October 9
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
- InventHelp Inventor Develops New Repair Accessory for Footed Pajamas (LJD-401)
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- SureFlow to Showcase AI and Eco-Technology Energy Management Solutions at GITEX 2024
"Traditional biopsies can be costly, invasive, and ultimately infeasible for many patients with advanced, metastatic lung cancer who have poor performance status. As more targeted treatments gain approval and complicate clinical decision-making, oncology care providers will need greater familiarity with next-generation tools that allow us to realize the fullest potential of precision oncology. A wider adoption of liquid biopsy, namely cell-free DNA analysis, is eagerly awaited," notes Christian Rolfo, MD, PhD, president of the International Society of Liquid Biopsy and deputy chair of the Educational Committee at the International Association for the Study of Lung Cancer.
In Oncology Innovations: The Role of Liquid Biopsy in Lung Cancer Management, participants will:
- Hone their decision-making skills and cultivate greater familiarity with best practices and recommendations made in the latest clinical practice guidelines.
- Rate the quality of care provided in multiple case scenarios and reflect upon aspects of care that can be further refined.
- Identify strategies to overcome logistical barriers to using liquid biopsies in practice (e.g., payer obstacles).
- Reinforce the value of liquid biopsies in the management of patients with lung cancer.
More on Nyenta.com
- How Long Does Ambien Stay in Your System?
- Winners of the 2024 Gerald Loeb Awards Announced by UCLA Anderson at New York City Event
- Smart Merchant Solution goes BLUU to strengthen its position in the Point of Sale (POS) Solutions and Payments Processing Sector
- EchoStar Corporation Announces Exchange Offers and Consent Solicitations for 0% Convertible Senior Notes due 2025 and 3.375% Convertible Senior Notes due 2026 Issued by DISH Network Corporation
- Apereo Foundation's Xerte Project turns 18!
Source: DKBmed
0 Comments
Latest on Nyenta.com
- After 300 miles of New York City driving, AMCI Testing's latest evaluation of Tesla FSD ( Supervised) demonstrates it is clearly not capable of self-driven taxi duty
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGR
- EFLOW FX Pioneers Tokenized Real Estate for Greater Accessibility and Growth
- Rochester: Statement by Mayor Malik D. Evans Regarding Walgreens Store Closures
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
- Rochester Central Library makes local history: First public library to send youth to nation's capital
- Rochester: Final Community Garage Sale and Super Flea of 2024 Sunday at Public Market
- New Rochelle: NR Youth Bureau -Healthy Bites Program
- Reality TV Star Vanessa Valente Gets Candid About Life After Temptation Island on Sisters Uncensored
- NEMTAC Announces Public Comment Period for the NEMTAC 3001-202X Transportation Specialist Education Draft Standard
- What is the Power of We Hosts Together Moving Summit to Combat Gender-Based Violence
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sprinklr, Inc. - CXM
- Only Two Weeks Until Creative Tech New York 2024
- New Rochelle Youth Bureau Presents: Mommy & Me Halloween Party
- OpsVeda Is Now Available Through AWS Marketplace
- NFL, College Teams Continue to Expand The Lineup For Third Annual Coach Knapp Stair Climb Campaign